A shortage of the drug against repeated heart attacks has been recorded in Russia – Kommersant
[ad_1]
In Russia, there is a “decrease in the volume of release into civilian circulation of the drug “effient” (prasugrel) from the American pharmaceutical company Eli Lilly,” he told the newspaper “Vedomosti” representative of the Ministry of Health of the Russian Federation.
The reasons for the drug shortage are not specified. The Ministry of Health emphasized that at the moment, information “about the cessation of supplies from the manufacturer has not been received by Roszdravnadzor.”
The general director of the Zdravcity pharmacy marketplace, Dmitry Popov, told the newspaper that the Servier company (the official distributor of Effient in Russia) notified its partners that supplies of the drug to Russia were stopped in September 2023. Mr. Popov emphasized that the distributor currently has no plans to resume supplies of this drug to the country.
Effient (prasugrel) is prescribed to prevent stent thrombosis in acute coronary syndrome. In addition, the drug is used to prevent thrombotic complications in patients with acute coronary syndrome who undergo percutaneous coronary intervention. “Effient” is also prescribed to patients with unstable angina or myocardial infarction (the drug helps prevent cases of recurrent infarction).
[ad_2]
Source link
